The Washout Meets the Proof: A Ten-Year-Best Year Closes at Thirteen Times Earnings, Margins Inflect, and Symplicity Finally Gets a Number — Maintain Outperform

Results vs. Consensus

Q4 FY2026 Scorecard

FY2026 Full-Year Summary

Quarter-Over-Quarter Comparisons

Quality of Beat

Revenue: the fourth consecutive quarterly organic acceleration (4.8% → 5.5% → 6.0% → 6.6%) landed against the year's most difficult comparison, which is what distinguishes this print from the prior three. Composition was the broadest yet: Cardiovascular +10.1% organic, MedSurg +5.1% (its best of the year, with the U.S. at +8%), Diabetes +8.1%, and only Neuroscience (+3.0%) below the company line — with its named catalyst, Stealth AXiS, having launched only in the quarter's final weeks. Geographic balance held at +7% U.S. / +6.2% international. The one flagged flatterer: ACM's 11% growth (Nellcor pulse oximetry mid-teens) was called out by the CFO as above-trend and expected to normalize — the kind of unprompted de-rating of a strong number that has become this team's signature.

Margins: the gross margin bridge tells the whole FY27 story in miniature. Pricing (+30bp) has now printed at the same level for four consecutive quarters — it's structural, not episodic. Cost-out net of inflation (+60bp) posted its best contribution of the year as the COGS programs matured. Mix (−60bp) narrowed from Q3's −100bp as CAS catheter pull-through began catching up to capital placements — the inflection the CFO promised for 2H FY27 is arriving early. Tariffs (−80bp, $74M) were in line. Below gross margin, the Blackstone payment distorts everything: the reported −230bp operating margin decline becomes roughly flat after removing the 160bp one-time payment and 80bp of tariffs — in a quarter where SG&A deliberately absorbed accelerated commercial investment (+30bp) against below-the-line favorability.

EPS: $1.55 versus $1.54 consensus, above the guide midpoint, with a 17.7% tax rate slightly better than planned. The −4.3% YoY decline headline requires the Blackstone context: the $157M payment — triggered by the FDA clearance of the MiniMed Flex pump, owed to the private-equity partner that funded its development — was a one-time, disclosed-in-April event that lands in adjusted results. Underlying it, FY26 closed at $5.53 against the April-revised $5.50–$5.54 — but $0.11 below the original November guide midpoint, a gap explained entirely by the MiniMed IPO dilution and the Blackstone charge. The honest summary: operationally, the company hit its numbers all year; corporately, the separation's financing mechanics cost shareholders a dime of FY26 EPS, and that dime is what the spring drawdown — in part — priced.

Segment Performance

Portfolio Revenue Mix — Q4 FY2026

Cardiovascular — The Share-Gain Machine Compounds

Cardiovascular grew 10.1% organic (U.S. +14%) for a second consecutive double-digit quarter. CAS grew 78% (U.S. +124%) and gained eight points of U.S. share in a single quarter — in a $14B market that grew ~20% — with global PFA up 145% and the U.S. Affera installed base up 40% sequentially. The business now annualizes above $2B at roughly 15% share. The ecosystem build accelerated: Prism-2 next-generation mapping software rolling out globally (with hybrid impedance/magnetic mapping that visualizes non-sensor catheters), Sphere-9 launched in Japan, FDA approval for the U.S. VT pivotal secured, Sphere-360 launching in Europe with the U.S. pivotal "enrolling swiftly," and two ICE-catheter investments (Beluga Medical, CardioACC) extending the platform toward full EP visualization. CRM grew 5% with EV-ICD up mid-60s, Micra mid-teens, the 3830 lead high-teens, and a strong OmniaSecure U.S. launch. Structural Heart was flat — international strength against U.S. softness tied to the low-risk data — with weekly U.S. procedure volumes stabilized over the trailing eight weeks. Coronary declined; renal denervation more than offset it.

"The impact of CAS to our growth will be very similar next year to this year… In FY '27, we're thinking mid- to high-teens market growth, and we're going to grow north of 2x that of the market rate… We're about 15% share right now and marching towards market leadership in CAS." — Geoff Martha, Chairman & CEO

Assessment: eight points of share in one quarter is the kind of number that ends competitive debates — the question is no longer whether Medtronic wins in PFA but how quickly the installed-base annuity converts to margin. The 40% sequential installed-base growth guarantees catheter pull-through well into FY28. "2x market growth" at mid-to-high-teens market growth implies CAS sustains 30–40%+ in FY27 on a $2B+ base — the deceleration the bears modeled keeps not arriving on schedule.

Neuroscience — A Transition Quarter With the Platform Loaded

Neuroscience grew 3.0% organic (+6% international). CST grew 3% with Core Spine up 6% on share gains (ModuleX expansion, distributor conversions) and navigation up low-double-digits following the late-quarter Stealth AXiS launch — described as "off to a very strong start" with FDA clearances now spanning spine, cranial, and ENT plus CE Mark for spine and cranial. Specialty Therapies grew 3% with Neurovascular up 6% (hemorrhagic +11% on Neuroguard and Artisse adoption). Pelvic Health was flat — solid Altaviva growth offset by sacral-market softness. Neuromodulation grew low-single-digits, with the SPR Therapeutics acquisition (peripheral nerve stimulation, a 20%+ growth category) announced to rebuild momentum. Leadership changes: 25-year veteran and Neuroscience head Brett Wall departs this summer; Dr. Kweli Thompson moves over from CRM.

Assessment: the segment underdelivered all year, and FY27 is its show-me cycle — but the setup is the best in several years: AXiS sells into a 10,000-unit installed base where 50% of CST revenue is consumables pull-through, robotics penetration sits in the high-single-digits against navigation's 70%, Neurovascular has comp relief plus three new product vectors plus the Scientia guidewire acquisition, and Altaviva scales all year. Management's claim that "every single franchise in Neuroscience is going to accelerate" in FY27 is aggressive but mechanically plausible. The leadership transition during the acceleration year is the unquantifiable risk.

Medical Surgical — The Year's Best Quarter, With a Robot in It

MedSurg grew 5.1% organic (U.S. +8%), its strongest of the year. Surgical grew 3% globally, evenly split U.S./international, on high-single-digit Advanced Energy and Wound Management plus — for the first time named as a contributor — Hugo, partially offset by ongoing bariatric pressure. Endoscopy grew high-single-digits (EndoFlip adoption, Nexpowder share gains). ACM grew 11% (Nellcor mid-teens) with management pre-normalizing the number for FY27 models. The Hugo file thickened materially: U.S. urology launch live with positive surgical-team feedback and rising smooth-case rates, worldwide procedure growth running 2–3x the market, the general surgery + gynecology + LigaSure RAS 510(k) submissions filed in late April, ProGrip Advanced (robot-optimized hernia mesh) cleared, and Touch Surgery past 1,400 installations, up 30%+ sequentially.

Assessment: Surgical at 3% with Hugo "contributing" is the first evidence the robotics headwind can become a tailwind. The general-surgery submission is the franchise-defining one — urology opened the door, but hernia and gyn are where the procedure volume lives, and the ProGrip clearance signals the instrument ecosystem is being staged ahead of the indication. We continue to model MedSurg conservatively (management itself hasn't extrapolated Q4's run-rate into the guide), but the option we carried at zero for three years now has observable value.

Diabetes (MiniMed) — Public, Growing, and Leaving the Building

Diabetes grew 8.1% organic (+15% reported) on international execution and U.S. CGM momentum with new patient starts building — ahead of the MiniMed Flex commercial launch this summer. The MiniMed IPO completed in early March, establishing the standalone company (which held its first earnings call the same morning); Medtronic remains majority shareholder through the split. The CFO flagged that Medtronic-reported Diabetes financials and standalone MiniMed financials are prepared on different bases — RemainCo modeling guidance arrives post-split, with updated metrics and share count.

Assessment: the operating business is performing — the IPO pricing was the disappointment (20% below range at $20, ~$560M for ~10%), and it cost Medtronic both FY26 EPS (the dilution mechanics) and narrative (the separation-value-unlock thesis took a public mark). The FY27 guide's conservative choice to assume full-year consolidation converts separation timing from a risk into a disclosed upside: a pre-year-end split — management's stated intent — adds share-count benefit the guide excludes.

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: assured and expansive, with none of the defensiveness a 26% drawdown might have produced — management treated the spring's stock action as somebody else's problem and the operating results as self-evident, which the numbers largely supported. The disclosure pattern continued to mature: launch metrics that were qualitative in February became quantitative in June (Symplicity's $100M, Altaviva's 3x implanters, Hugo's 2x–3x procedure growth), and the FY27 guide was built with every contentious assumption stated aloud. The two carefully-managed subjects were Structural Heart, where "stabilized over the last 8 weeks" did a lot of work, and the MiniMed IPO, discussed entirely in operational rather than valuation terms.

1. The Margin Inflection Arrived On Schedule — The February Promise, Kept

Q4 adjusted gross margin rose 30bp year-over-year — the first YoY expansion of the fiscal year — with the strongest cost-out print of the year (+60bp net of inflation) and the narrowest mix drag (−60bp versus Q3's −100bp) as CAS catheter sales began catching up to capital placements. Management confirmed the dynamic extends: CAS mix "getting better" with margin improving, less of a headwind in 2H FY27, and the Diabetes mix pressure disappearing entirely upon separation.

Assessment: our February note said a Q4 that delivered margins-up-plus-6%-organic "resolves the only honest bear argument left." It delivered both. The margin algorithm — 70–80bp/year operational engine, mix turning from headwind to neutral-to-positive, tariffs as a bounded step — has now been demonstrated rather than promised, one quarter earlier than the CFO's own 2H-FY27 inflection date. This is the single most important fact in the print for the FY27–28 earnings power case.

2. Symplicity Gets a Number: $100M Annualizing, Procedures Doubled

The renal denervation launch graduated from funnel metrics to financials: average weekly procedure volumes have doubled since the NCD, the business annualizes at ~$100M, the physician finder spans 200 doctors across 300+ accounts, and prior-authorization approvals are ramping. The clinical moat deepened with late-breaking three-year data at CRT: in 2,000+ patients, sustained systolic reductions of 13.3mmHg (ambulatory) and 18.1mmHg (office), with 90% of patients deriving meaningful benefit — against the epidemiological anchor that a 10-point reduction drives a >20% reduction in major cardiovascular events.

"Ardian is now annualizing about $100 million revenue a year, and we expect that to continue to grow significantly into '27 and beyond." — Thierry Pieton, CFO

Assessment: the first revenue disclosure lets us calibrate the ramp against the $400M-by-roughly-FY28 marker management allowed to stand in November: $100M annualizing roughly two quarters post-NCD requires a ~4x over ~8 quarters — steep, but the doubling-every-quarter procedure cadence and the 300-account base make it arithmetic rather than fantasy if conversion holds. The three-year durability data matters more for the terminal value: hypertension therapies live or die on persistence, and 90%-meaningful-benefit at three years is the number that referring physicians will actually quote.

3. CAS: Eight Points of Share and the "Surround the EP" Doctrine

Beyond the headline growth, the strategic frame sharpened: Prism-2 mapping software (visualizing non-sensor catheters via hybrid impedance/magnetic mapping), two ICE-catheter investments for real-time cardiac visualization, the VT pivotal approval (a high-acuity indication expansion), Sphere-9 in Japan, and Sphere-360 launching in Europe — collectively described as a plan to "completely surround the electrophysiology space." Asked directly whether the Affera platform would open to third-party catheters, management declined: the plan is proprietary technology and tight workflow.

Assessment: the walled-garden answer is the economically correct one at 15% share and climbing — openness is what sub-scale platforms offer. The ecosystem investments (ICE, mapping software, single-shot, VT) are about making each Affera placement harder to displace and each EP lab more fully captured. The competitive risk worth respecting: the largest incumbent retains field-force scale and is not standing still on single-shot. Sphere-360's European reception — "early physician feedback is really strong" — is the next verifiable claim.

4. The FY27 Guide: Conservative By Construction, With the Upside Itemized

The first formal FY27 guide — 6.75–7.25% organic (including ~125bp from the 53rd week and ~25bp from Diabetes; Q1 at 11.5–12% with 500–600bp of week benefit) and EPS of $5.90–$6.00 (+6.7–8.5%) — was built with every conservative choice disclosed: full-year Diabetes consolidation with monthly dilution and no share-count benefit (a pre-year-end split, management's stated intent, is upside), 2% M&A dilution (up a point as deals closed early), the full $250M tariff load with no government-refund assumption (refunds have been applied for), a ~1-point fuel/transportation headwind from the Middle East conflict, and FX at only neutral-to-+1%.

"We started the year with a 5% guidance. Gradually, we increased it to 5.5%. We ended the year at 5.8%. The midpoint of our guidance for '27 is right at that level, 5.8% [ex-week]. So I think we're positioning the business for success going into this year." — Thierry Pieton, CFO

Assessment: the ex-week midpoint equal to FY26's exit rate looks like guided deceleration until you weight the comps: FY27 laps four consecutive acceleration quarters, and the FY26 pattern (guide 5%, deliver 5.8%) is the template management just told you to apply. The EPS construction is the more consequential signal — between separation timing, tariff refunds, and FX, there are three disclosed paths above the range, and none below it that management hasn't already absorbed into the numbers. After a year in which every guide was met or beaten, the under-promise architecture enters FY27 intact.

5. The M&A Cadence: ~$2B Deployed, Six Names, One Pattern

Q4-to-date capital deployment reached nearly $2B across the announced complex: CathWorks closed (FFRangio — AI-driven, wire-free FFR attacking a $1B segment growing low-double-digits, with positive one-year ALL-RISE data), Scientia Vascular (neurovascular guidewires — "every neurovascular procedure starts with Medtronic"), SPR Therapeutics (peripheral nerve stimulation, 20%+ category growth), Beluga Medical and CardioACC (ICE catheters), the Pulnovo investment (pulmonary artery denervation — the Ardian playbook applied to a new vascular bed), and a Merit Medical distribution agreement (ViaVerte, vertebrogenic back pain). Sixteen venture investments totaling ~$250M were made in FY26; recent M&A contributes ~$150M of FY27 inorganic revenue.

Assessment: the pattern is disciplined to the point of being formulaic — every transaction either deepens an ecosystem Medtronic already leads (ICE/mapping into Affera, guidewires into neurovascular, PNS into pain) or replicates a proven playbook in a new bed (Pulnovo as Ardian-for-pulmonary-hypertension). Nothing transformational, nothing balance-sheet-straining, everything dilution-disclosed. With $9.2B of cash and FCF at decade highs, the capacity for the "several billion dollar" tuck-in remains unused — dry powder as strategy, not indecision.

6. Hugo: From Cleared to Contributing in One Quarter

The U.S. urology launch progressed from first cases (February) to named revenue contribution within the Surgical line (Q4), with worldwide procedure growth at 2–3x market, utilization rising, smooth-case rates improving, and installations stepping up in and outside the U.S. The late-April FDA submissions for general surgery and gynecology — plus LigaSure RAS and the cleared ProGrip Advanced mesh — stage the volume indications, while Touch Surgery (1,400+ installs, +30% sequential) builds the digital moat. Management's stated ambition: talk about the enabling-technology ecosystem the way it talks about AiBLE in spine.

Assessment: the robotics conversation has changed registers — from "does Hugo exist commercially" to "how fast does the indication stack build." General surgery approval (likely 2H FY27 on normal 510(k) cadence) is the unlock; until then, Hugo's contribution is real but small, and the AiBLE analogy is the right mental model: the robot is the wedge, the ecosystem is the business.

7. Structural Heart: Stabilization as the New Bull Case

The quarter's weakest franchise was addressed head-on: flat overall, with U.S. softness attributed to the Evolut low-risk data (an "older technology, old procedure" issue, U.S.-weighted because it concerns a large-size valve more used domestically), and — the load-bearing claim — weekly U.S. procedure volumes stable for 8–10 weeks. The response stack: DASI software investment, internal mitral and tricuspid replacement programs, the Anteris balloon-expandable investment, and "fresh leadership running fast."

Assessment: "stabilized" is doing heavy lifting, and we'd characterize the franchise as structurally challenged rather than recovering — the low-risk data is permanent, the U.S. competitor is executing, and the fixes are all multi-year. But the guide treats it that way too ("prudent guidance for Structural Heart"), which is the right way to carry a wounded franchise: assume nothing, let any recovery be upside. TAVR is now the cheapest option in the portfolio — priced for nothing, with three separate recovery vectors.

8. Altaviva: The Conversion Quarter

The tibial launch moved from training to treating: active implanters up 3x sequentially, patients treated up 2.5x, nearly 1,000 physicians trained, and prior-authorization throughput accelerating as physicians gain experience. The product claims sharpened — same-day activation, 15-year longevity, full-body MRI access with the device on.

Assessment: 3x implanter growth off a launch quarter is the steepest early adoption curve among the four drivers, consistent with the thesis that the patient-experience gap versus sacral and Botox is widest here. The watch item is the offset: sacral-market softness held Pelvic Health flat, so Altaviva must outgrow its own franchise's erosion before the segment shows it. We expect visible Pelvic Health acceleration by 2H FY27.

9. The Dividend's 49th Raise, and What $9.2B of Cash Is For

The quarterly dividend rose to $0.72 ($2.88 annualized, a ~3.7% yield at the pre-print price) — the 49th consecutive annual increase — alongside $4.2B of FY26 capital returns and a $9.2B year-end cash and investments position explicitly framed as M&A capacity.

Assessment: the dividend aristocracy (one year from the 50-year mark) remains the valuation floor under the stock — at the June 2 close, MDT yielded within sight of 4%, a level that has historically marked institutional accumulation zones for this name. The capital priorities are now legible: dividend sacrosanct, buyback opportunistic, M&A the growth lever, all funded by decade-best FCF.

10. Leadership Rotation in the Acceleration Year

Neuroscience EVP Brett Wall — 25 years, architect of the interventional stroke standard of care — departs this summer, succeeded by Dr. Kweli Thompson, most recently running CRM through its strongest stretch in years. The transition was framed as planned.

Assessment: promoting the executive who just ran the portfolio's steadiest outperformer into its most catalyst-dense segment (AXiS, Altaviva, Scientia, SPR all land in FY27) reads as deliberate sequencing rather than succession risk — but Neuroscience has now missed expectations two consecutive quarters, and the new leadership owns an acceleration commitment ("every single franchise") made on its predecessor's watch.

Guidance & Outlook

The guide's framing battle — fought openly in Q&A — is whether 5.5–6.0% ex-week organic growth against FY26's 5.8% constitutes acceleration. Management's answer was the FY26 pattern itself: guide at 5%, raise to 5.5%, deliver 5.8%. Setting the FY27 ex-week midpoint at the FY26 exit rate — while lapping four acceleration quarters, assuming ACM normalizes, holding Structural Heart at stabilization, and crediting no tariff refunds — is the same under-promise that preceded two raise-quarters last year. The segment-level construction supports the read: Cardiovascular "in line with FY26," every Neuroscience franchise accelerating, MedSurg deliberately guided below its Q4 run-rate, and Symplicity/Altaviva/Hugo all early-curve.

Implied trajectory: Q1's optics will be enormous (11.5–12% organic, EPS $1.38–$1.40) on the week benefit, then normalize. The margin shape inverts FY26's: tariff carryover compresses 1H, then 2H delivers the step-up as tariffs lap, CAS mix turns accretive, and (if the split lands) Diabetes deconsolidates. FY28 — with tariffs lapped, the 53rd week reversing, separation complete, and the launch drivers scaled — is where the algorithm shows clean.

Street at: consensus enters FY27 near the guide's EPS midpoint after the spring's forced reset — the first time all year the Street starts at management's number rather than above it. That's the setup the under-promise machine was built for.

Guidance style: five for five on organic guides this fiscal year, every EPS guide met or beaten operationally, every negative pre-disclosed. The April cut — the year's one downward revision — was transaction mechanics, not operations, and was communicated the way everything else has been: early, itemized, and exactly once.

Analyst Q&A Highlights

What Offsets CAS If It Slows? The Guide-Construction Walk

The opening question accepted the ex-week math (~5.5–6.0% underlying) and asked which segments accelerate to offset a slowing CAS. Management first rejected the premise — CAS's growth contribution in FY27 will match FY26's, at 2x a mid-to-high-teens market off a much larger base — then walked every segment: Cardiovascular in line with FY26, every Neuroscience franchise accelerating (AXiS pull-through on a 50%-consumables CST base, Neurovascular innovation, Altaviva), MedSurg guided below its Q4 run-rate, MiniMed adding 20–25bp.

Q: "Fiscal '27, excluding the extra week, I think underlying 5.5% to 6%, that's an acceleration in line with prior assumptions. I think as CAS slows down, that's been a concern for the market, right? Can you just talk about what are the offsets? What segments accelerate to offset CAS and drives the confidence in this 5.5% to 6% organic?"
— Vijay Kumar, Evercore ISI

A: "The impact of CAS to our growth will be very similar next year to this year… we're going to grow north of 2x that of the market rate… We started the year with a 5% guidance. Gradually, we increased it to 5.5%. We ended the year at 5.8%. The midpoint of our guidance for '27 is right at that level… I think we're positioning the business for success going into this year."
— Geoff Martha, Chairman & CEO; Thierry Pieton, CFO

Assessment: the most complete segment-by-segment guide decomposition of the cycle, and the "5% → 5.5% → 5.8%" framing is management explicitly teaching the market to treat the new midpoint as a floor. The CAS premise-rejection is checkable: 2x a mid-to-high-teens market means ~30–38% CAS growth in FY27 — write it down and grade it quarterly.

TAVR: How Bad Was the Share Damage, and What's Assumed?

The concentrated bear topic got a direct airing: what did the Evolut 6/7-year low-risk data do to share, how did U.S. and international differ, and what does the guide assume? Management quantified the dynamic qualitatively — a U.S.-weighted slowdown tied to the data on an older, large-size valve and superseded procedural technique, minimal international impact — anchored on eight-to-ten weeks of stable weekly procedure volumes, and confirmed the guide models stabilization, not recovery.

Q: "The Evolut 6- and 7-year data did get a lot of attention… What did you see from a share standpoint in your TAVR business in fiscal Q4? Was there any differences U.S. versus international? And what are you assuming for your TAVR business in fiscal '27?"
— Larry Biegelsen, Wells Fargo Securities

A: "The business has stabilized, right? Over the last 8 to 10 weeks, it's been stable. We did experience a slowdown in growth, and it really was tied, we believe, to the low-risk data… it's an older technology… the procedure tactics we've changed, and it's limited to a large-size valve, which is more used in the United States… In Q4, we grew 6.6% despite the headwind… what we've seen over the last 8 weeks is a stabilization of that business, and that's what we've modeled going forward."
— Geoff Martha, Chairman & CEO; Thierry Pieton, CFO

Assessment: the answer was honest about causation and conservative in modeling — the two things that matter. What it didn't offer: a share number, or a recovery case. We treat U.S. TAVR as structurally impaired and note the portfolio just demonstrated it can absorb a flat Structural Heart quarter and still accelerate.

When Does Hugo Stop Being an Investment and Start Being a Business?

Asked when Hugo shows up in Surgical growth and when it turns P&L-positive, management confirmed Hugo contributed to Q4 as promised, walked the leading indicators (smooth-case rate, procedures meaningfully up, utilization strong, placements building), and framed the destination as an enabling-technology ecosystem narrative — AiBLE for surgery — while declining to date the margin crossover.

Q: "On Hugo, when does that start to show up on the surgery growth? And when do you expect Hugo to start contributing positively to the margin and EPS profile versus being an R&D investment, and how to think about the return on that program?"
— Travis Steed, BofA Securities

A: "We had told you that we thought Hugo would have an impact towards the end of FY '26, and it did in Q4… the smooth case rate is up… Our procedures are meaningfully up and utilization continues to be strong… I want to get to the point where we're talking about the enabling technology, not just Hugo… kind of like we do in spine, with AiBLE."
— Geoff Martha, Chairman & CEO

Assessment: the P&L question went unanswered, which is itself the answer — Hugo remains margin-dilutive through the indication build-out, likely into FY28. The AiBLE framing is the right strategic tell: Medtronic is building a capital + consumables + digital stack, not a robot SKU, and will report it accordingly when the numbers flatter.

The Second-Half FY27 Gross Margin Step-Up Case

A construction question — tariffs lap mid-year, MiniMed may deconsolidate, so what constrains the 2H gross margin? — produced the cleanest forward margin walk of the call: $65M/quarter of tariff carryover in 1H only, continued pricing lift, improving net cost-out, CAS mix turning less negative as catheter share rises, and Diabetes mix pressure vanishing on separation — netting to flattish-to-slightly-up full-year gross margin ex-tariffs with a stronger 2H, plus SG&A-driven operating leverage on accelerating revenue.

Q: "Assuming you lap some of these tariff dynamics kind of midway through fiscal year '27, potentially MiniMed is coming off… it would seem that there is opportunity potentially for a gross margin step-up particularly in the second half of 2027. And so is there anything else that we should be considering in terms of constraining gross margins?"
— Ryan Zimmerman, BTIG

A: "If we are to separate Diabetes before the end of the year, which is our intent, then we should see some lift in the gross margin rate… the other dimension of the mix impact is coming from CAS. It's actually getting better because the margin of CAS is improving… And then the good news is growth is accelerating, and with growth we're getting operating margin leverage… we'll have accretion in operating margin, in particular in the second half of the year."
— Thierry Pieton, CFO

Assessment: nothing constrains the 2H step-up except execution — the CFO effectively endorsed the premise. The 2H-FY27 margin acceleration is now the single most consensus-checkable claim in the model, and the first half's guided softness (tariff carryover) sets up the same trough-then-proof pattern that played out across FY26.

Why Separate MiniMed If It's Inflecting?

The strategic challenge: consensus models strong MiniMed growth and margin improvement — why divest an inflecting asset? Management's answer had three legs: the remaining growth drivers monetize Medtronic's shared platforms (robotics, commercial footprint) in ways Diabetes doesn't; capital allocation discipline argues against funding a structurally lower-margin segment when the rest of the company now grows nearly as fast; and the growth gap between MiniMed and RemainCo has compressed to the point where the diversification benefit no longer pays for the margin drag.

Q: "I see consensus numbers have strong organic sales growth, margin and free cash flow improvements over the coming years. If that's the case, can you just remind us what's the rationale for separating it here? Wouldn't you want to keep a business with strong improvements and inflections in profitability and growth going forward?"
— Robbie Marcus, JPMorgan

A: "We're separating it not because of our confidence in the outlook of the business… it's a structurally lower-profitable segment. And so it's kind of hard to allocate capital that way. I think both businesses will do better separated… the gap between MiniMed and the rest of Medtronic isn't as much as it used to be in terms of growth."
— Geoff Martha, Chairman & CEO

Assessment: the answer concedes the question's premise — MiniMed is a good business being sold below intrinsic value (the IPO priced 20% under range) — and defends the decision on portfolio-construction grounds that are sound for RemainCo even if the exit price stings. The unspoken half: the separation's margin and focus benefits were promised to the activist, and reversing course was never on the table.

Walled Garden Confirmed: The Affera Platform Stays Proprietary

A two-part question probed whether the ICE investments and Prism-2's ability to visualize non-sensor catheters presage an open Affera ecosystem, and asked for the latest tariff-policy read (USMCA, Section 232). Management closed the open-platform door — proprietary technology, tight workflow, best outcomes — while the CFO confirmed the guide embeds tariff status quo with applied-for refunds as unmodeled upside.

Q: "You talked about visualizing other catheters on Affera and how you were thinking about integration of some of the investments you're making… as well as the potential to integrate some of the other established technologies onto Affera… And then… there do seem to be a lot of other unresolved considerations on tariffs, such as USMCA and then 232."
— David Roman, Goldman Sachs

A: "If your question is about are we opening the system, I don't think we have plans for that right now… we're really building out our proprietary technology and ensuring that we have that tight workflow… [On tariffs:] we've incorporated sort of a status quo… we haven't incorporated any potential upside from reimbursements that could occur, which we have applied for."
— Geoff Martha, Chairman & CEO; Thierry Pieton, CFO

Assessment: the closed-ecosystem call is high-conviction strategy with a known failure mode (if a rival's catheter becomes clinically indispensable, closed platforms bleed accounts) — but at current share-gain velocity, Medtronic has earned the right to bet on its own stack. The tariff-refund disclosure quietly plants another upside flag in the guide.

China: The Question Nobody Had Asked in a Year

The China exposure check produced a steady-state answer: a growth end-market growing at the corporate average with strong profitability, VBP "here to stay" but the worst behind, minimal manufacturing-for-export exposure, and volume gains plus cost-outs offsetting tender pricing.

Q: "Historically, China has been a growth channel. There have been some headwinds with VBP for a couple business units. But what's the outlook for 2027?… is the China franchise going to be accretive or dilutive to the organic revenue growth guidance?"
— Josh Jennings, TD Cowen

A: "We've had to navigate a number of these VBP, and I think VBP is here to stay. The worst is behind us… It remains growing at the corporate average right now, and that average for the company is improving… it's still accretive from a profitability standpoint, and it's a growth region for the company."
— Geoff Martha, Chairman & CEO

Assessment: China-at-corporate-average is a materially better posture than most large-cap medtech peers can claim, and the de-risking happened gradually enough that the market never repriced it. Neutral-to-mildly-positive for the FY27 construct.

What They're NOT Saying

1. FY26 EPS finished $0.11 below the original November guide midpoint: the year's bottom line was cut in April — via press release, between calls — for the Blackstone milestone and IPO dilution. The Q4 narrative ("ahead of expectations") is true against the revised bar and silent about the original one. Operationally clean, corporately costly.
2. The MiniMed IPO's valuation never came up: "completed the IPO" elides pricing 20% below the marketed range and breaking issue on day one. The separation-value-unlock argument — a pillar of the August 2025 Elliott-era thesis — took a public mark-to-market, and the split's share-retirement math now keys off a weaker currency.
3. "Acceleration" leans on the 53rd week: the headline 6.75–7.25% organic guide owes ~125bp to the calendar and ~25bp to Diabetes; the ex-week midpoint equals FY26's exit rate. Management was transparent about the math in Q&A while letting the headline number carry the press release.
4. The April cybersecurity incident was never mentioned: the disclosed unauthorized IT-systems access that contributed to the spring drawdown received zero airtime — no remediation update, no cost quantification, no questions either.
5. The Investor Day has quietly slipped: "mid-calendar 2026" is now; no date exists. The new long-term financial targets promised at the August 2025 Elliott announcement remain unissued — the FY27 guide partially fills the void, but the strategic framework (and the activist's scorecard) is overdue.
6. RDN's $100M run-rate versus the $400M marker: management reaffirmed enthusiasm but not the November arithmetic ("disappointed if year five" for $400M U.S.). At $100M annualizing with procedures doubling, the FY28 path requires sustained doubling — achievable on current cadence, but the cadence itself is two quarters old.
7. Structural Heart's "stabilization" baseline is undisclosed: stable for 8–10 weeks — at what level? The franchise was flat in Q4 overall; U.S. TAVR's actual run-rate decline, the share ceded, and the recovery threshold all remain outside the disclosure perimeter.
8. Q1 FY27's optics are pre-loaded: 11.5–12% organic and $1.38–$1.40 EPS will print as blowout headlines carrying 500–700bp of pure calendar benefit. The same machine that pre-announced the Q3 trough is now pre-building a Q1 victory lap — symmetric behavior, worth adjusting for in both directions.

Market Reaction

• Pre-print setup: MDT entered the print at $73.75, down ~26% from its February level and ~27% from the November high — a four-month grind lower driven by the below-range MiniMed IPO (March), the $0.12 April guidance cut (Blackstone milestone + IPO dilution), late-April analyst target cuts, a cybersecurity disclosure, the TAVR low-risk-data wobble, and tariff/fuel-cost macro pressure. At ~13.3x the revised FY26 guide with a ~3.9% indicated yield, the stock entered the print at its cheapest valuation of the fiscal year, with positioning maximally washed out.
• Day-of session: shares were indicated up ~7% premarket, opened at $77.12 (+4.6%), and closed at $77.95, +5.7% versus the prior close on 20.3M shares (~1.4x average) — the largest post-earnings gain of the fiscal year, retracing roughly two weeks of the drawdown in a session.

The reaction decomposes cleanly: a washed-out multiple met (1) the year's best organic print on its hardest comp, (2) the gross margin inflection management had dated in February, delivered, (3) the first hard revenue numbers from the launch portfolio — Symplicity's $100M annualizing being the headline conversion of narrative into financials — and (4) an FY27 guide whose conservative construction (full-year Diabetes consolidation, no tariff refunds, ACM normalized) was legible to anyone who has watched this team guide for four quarters. The market spent the spring pricing the separation's financing costs; the print forced it to re-price the operating business those costs were funding.

The four-month round trip carries a lesson for positioning through the rest of the separation: MiniMed-related mechanics (split timing, share retirement, RemainCo re-guide) will continue to generate optically negative, operationally empty headlines, and the under-promise guidance machine will continue to make even strong quarters look routine at the guide line. The volatility is structural until the split completes; the operating trajectory underneath it has now accelerated for four consecutive quarters.

Street Perspective

Debate: Is Thirteen Times Earnings a Mispricing or a Verdict?

Bull view: a company compounding organic growth at a four-quarter-accelerating clip, with a demonstrated margin inflection, four scaling category launches, decade-best FCF, and a 49-year dividend record traded into the print at ~13x forward — a multiple reserved for secular decliners — purely on separation mechanics and one franchise's data wobble; the gap between operating reality and price is the widest in large-cap medtech.

Bear view: the market has watched Medtronic transitions before: FY26 all-in EPS grew 0.7%, FY27's guide needs a calendar week to clear 7% growth, the separation has already destroyed value once (the IPO pricing), TAVR is structurally losing share, and the "everything accelerates in FY27" claim asks for faith the stock's decade of history doesn't support.

Our take: the bear case is an argument about the past wearing the clothes of the present — every one of its components (EPS stagnation, separation costs, TAVR) is either one-time, disclosed, or contained, while the bull case's components (CAS share, margin engine, launch conversion) are compounding and verified quarterly. At 13x with a near-4% yield, the price asked for nothing to go right; Q4 demonstrated most things are. We re-underwrote at the lows rather than averaging down rhetorically: the thesis survives every stress except a genuine FY27 organic miss.

Debate: Does the FY27 Guide Hide Acceleration or Decoration?

Bull view: the ex-week midpoint matching FY26's exit rate — after guiding FY26 at 5% and delivering 5.8% — is the same sandbag with a new label; segment construction (ACM normalized, Structural Heart at stabilization, MedSurg below run-rate, zero tariff refunds, no split benefit) leaves five disclosed upside levers against none consumed.

Bear view: a company genuinely accelerating doesn't need a 53rd week to print a 7-handle, the comps get two points harder, CAS mathematically decelerates from 78%, and the upside levers (split timing, tariff refunds) are outside management's control — conservative construction is indistinguishable from a ceiling when the drivers are this mature.

Our take: grade the team on its record: four organic guides, four meets-or-beats, with the raises arriving mid-year both times the pattern was tested. The honest uncertainty is not the revenue line (the launch stack plus CRM/CST stability covers the bridge) but the EPS conversion through the separation window. We model 6.0–6.3% ex-week organic and $5.98–$6.05 EPS — above the guide, below euphoria.

Debate: Is TAVR a Contained Wobble or the First Crack?

Bull view: the low-risk data concerns an obsolete valve and superseded technique, volumes stabilized within ten weeks, international share is still rising, and the franchise is ~10% of revenue with three funded recovery vectors (DASI, mitral/tricuspid, Anteris) — a flat-to-slow TAVR is fully absorbed by a portfolio that just grew 6.6% with it flat.

Bear view: durability data is the currency of structural heart, the headline ("late mortality catch-up") attaches to the brand rather than the discontinued SKU, the U.S. competitor will run the data in every account for years, and "stabilized" at a stepped-down baseline is how share loss becomes permanent — with balloon-expandable entry still years from revenue.

Our take: we side with containment on portfolio math and with the bears on franchise trajectory — U.S. TAVR likely never recovers its prior share path, and we model it flat indefinitely. The investable question is whether that's priced: at the current multiple, a zero-growth TAVR is more than priced, and any Anteris/mitral progress is free. Watch international share and the cadence of competitive data releases.

Model Update Needed

Valuation impact: at $77.95, MDT trades at ~13.1x the FY27 guide midpoint ($5.95) with a ~3.7% yield — against large-cap medtech growth peers in the mid-20s and the stock's own five-year average in the mid-to-high teens. The spring de-rating embedded the separation's costs twice: once in the estimates (correctly) and once in the multiple (excessively). Re-rating merely to 16–17x on in-line FY27 delivery implies $95–$101; our prior $112–$120 framework — built on a FY28 view with the separation complete, tariffs lapped, and the launch portfolio scaled — remains intact on fundamentals but now implies ~45–55% total-return potential from the post-print price, which is the widest gap between our framework and the market since initiation. The position of maximum opportunity in this name is when separation mechanics obscure operating acceleration; that is the current configuration.

Thesis Scorecard Post-Earnings

Overall: thesis strengthened across every operating dimension while the stock de-rated on transaction mechanics — the canonical setup for forward outperformance. The fiscal year closed with four consecutive quarters of organic acceleration, a demonstrated margin inflection, all four generational drivers revenue-generating, and a guidance reset that starts FY27 with the Street at management's number for the first time in the cycle.

Action: maintain Outperform with increased conviction at the de-rated entry. Watch items for Q1 FY27 (August): the ex-week organic run-rate (strip the 500–600bp calendar benefit), Symplicity's sequential procedure cadence against the $400M-by-FY28 path, MiniMed split timing (each month earlier than year-end adds ~$0.01–$0.02 plus share-count benefit), Sphere-360's European uptake, and the overdue Investor Day date — the strategic-targets vacuum is the last unexecuted item from the August 2025 Elliott agenda.